Clinical
METiS BioTech Announces China’s First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
METiS BioTech; AI; drug formulation; Phase III; pseudobulbar affect (PBA); China; nanodelivery; AiTEM; clinical milestone
Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints
Addex Therapeutics, J&J, Phase II trial, epilepsy, drug candidate, clinical endpoints, future development.
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures